Whitehawk Q2 Loss Narrows to $16.6M, Cash Runway Extended to 2H 2028

summarizeSummary

Whitehawk Therapeutics reported a narrower Q2 2026 net loss of $16.6 million, extended its cash runway into 2H 2028, and advanced its ADC pipeline with three Phase 1 programs and new platform partnerships.

check_boxKey Events · Earnings and Guidance · WHWK

• Q2 Loss Narrows Significantly

  Net loss of $16.6M vs $52.6M in Q2 2025, driven by the absence of a $38M upfront license fee paid in the prior-year quarter.

• Cash Runway Extended to 2H 2028

  Cash, equivalents, and short-term investments totaled $190.0M as of June 30, 2026, up from $145.7M at year-end 2025, following the $87.5M private placement in May 2026.

• Pipeline Progress Across Three Assets

  Phase 1 trials for HWK-007 and HWK-016 continue enrolling; HWK-206 Phase 1 initiation on track for Q3 2026; initial data from HWK-007 and HWK-016 expected in 1H 2027.

• Platform Expansion via New Partnerships

  Option agreement with Hangzhou DAC for up to five additional ADC programs using CPT113; global collaboration with Biocytogen for bispecific antibody ADC development.

auto_awesomeAnalysis · WHWK · Life Sciences

Whitehawk's Q2 net loss shrank to $16.6 million from $52.6 million a year ago, largely because the prior-year quarter included a $38 million upfront license fee. The company ended June with $190 million in cash, enough to fund operations into the second half of 2028 — a critical survival signal for a clinical-stage biotech. The pipeline is advancing: Phase 1 trials for HWK-007 and HWK-016 are enrolling, and a third asset, HWK-206, is on track to start a Phase 1 study this quarter. New partnerships with Hangzhou DAC and Biocytogen expand the ADC platform's long-term potential. The results beat consensus loss estimates and remove near-term financing risk, but the company remains pre-revenue and heavily dependent on clinical execution.